Tanvir Khaliq

Education

1. Postdoc - Medicinal Chemistry
University of Kansas and University of Florida

2. Ph.D. - Medicinal Chemistry
Central Drug Research Institute

3. Teaching Certificate in Pharmacy
University of Florida

Academic Interests

• Parasitic diseases
• Drug discovery
• Medicinal chemistry
• Organic synthesis
• Pharmacokinetics

Academic Responsibilities

1. PHA 340 - Medicinal Chemistry I
• Organic functional groups and their relevance to physicochemical and ADME properties
• Heterocycles
• Stereochemical principles
• ADME (absorption, distribution, metabolism, and excretion)

2. PHA 341 - Medicinal Chemistry II
• CNS depressants and stimulants
• Local anesthetics
• Opioid analgesics and antagonists
• Nonsteroidal anti-inflammatory drugs (NSAIDs)

3. PHA 721 - Advanced Concepts in Medicinal Chemistry
• Drug design
• Enzyme inhibition and inactivation

Committee Activities

1. Faculty Development Committee
2. PharmD Accreditation Committee
3. Curricular Progression and Variation Committee
4. Scholarship and Awards Committee

Awards and Honors

1. Medicinal Chemistry (MEDI) award by the American Chemical Society
2. Travel grant by the International Narcotic Research Committee
3. Junior Research Fellowship
4. Senior Research Fellowship

Grants

1. South Dakota Board of Regents Competitive Research Grant FY23
Title: Structure-activity relationships of peganine for antileishmanial activity
Role: Principal Investigator
Status: Recommended for funding

2. South Dakota State University 3D (Drug, Disease, and Delivery) Research Center
Title: Design, synthesis, and biological evaluation of novel analogs of quinazoline alkaloid-based natural products for the protozoan parasitic diseases leishmaniasis and trypanosomiasis
Role: Principal Investigator
Status: Start-up funding

3. National Institute on Aging
Title: Recombinant neurotrophic factor for cognitive deficits in Alzheimer’s disease
Role: Co-Investigator
Status: Pending

Patents

1. Duffey, T. A.; Khaliq, T.; Gelb, M. H.; Scott, R. C.; Turecek, F.; Wolfe, B. J.
Mass spectrometric compositions and methods for lysosomal storage disease screening WO2012027612A1, Mar 1, 2012.

Professional Memberships

1. American Chemical Society
Divisions of Organic, Medicinal, and Biological Chemistry

2. Rho Chi Honor Society

Area(s) of Research

Work in Dr. Khaliq’s laboratory is primarily focused on anti-parasite drug discovery and development. Research focusses on the rational design and synthesis of novel analogs of natural products as anti-parasite agents for their potential development as treatments against leishmaniasis and trypanosomiasis which have led to a devastating impact on public health in the developing world. A major emphasis is on developing cost-effective and orally active molecules that are also active against the drug-resistant strains. One of the current projects in his laboratory is exploring the structure-activity relationships (SAR) of a structurally novel and an orally active quinazoline alkaloid to optimize its anti-parasite activity against the clinically relevant intracellular Leishmania parasite. The compounds are studied both in vitro against the intracellular parasites and in vivo in murine visceral leishmaniasis model. Selected compounds are evaluated for their pharmacokinetic properties and against the clinically-resistant strains to facilitate their potential development. The laboratory utilizes both classical medicinal chemistry and structure- and ligand-guided approaches to design novel compounds and uses efficient synthetic procedures for the rapid generation of the rationally designed molecules.

Selected Publications:

1. Khaliq, T.; Joshi, A.; Senadheera, S. N.; Lunte, S. M.; Aldrich, J. V. Preclinical pharmacokinetic properties of the novel macrocyclic peptide kappa opioid receptor ligands CJ-15,208 and [D-Trp]CJ-15,208. (In-preparation)

2. Khaliq, T.; Brice‐Tutt, A. C.; Stacy, H. M.; Coleman, J. S.; McLaughlin, J. P.; Aldrich, J. V. Preclinical evaluation of the orally bioavailable macrocyclic mixed opioid agonist/antagonist tetrapeptide cyclo[Pro-Sar-Phe-D-Phe]. (In-preparation)

3. Khaliq, T.; Aldrich, J. V. Structure-metabolism relationships of novel macrocyclic peptide kappa opioid receptor ligands. (In-preparation)

4. Brice‐Tutt, A. C.; Senadheera, S. N.; Ganno, M. L.; Eans, S. O.; Khaliq, T.; Murray, T. F.; McLaughlin, J. P.; Aldrich, J. V. Phenylalanine stereoisomers of CJ‐15,208 and [D‐Trp]CJ‐15,208 exhibit distinctly different opioid activity profiles. Molecules 2020, 25, 3999.

5. Khaliq, T.; Williams, T. D.; Senadheera, S. N.; Aldrich, J. V. Development of robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist D-Trp [CJ 15,208] in plasma and application to a pharmacokinetic study. J. Chromatogr. B 2016, 1028, 11-15.

6. Shivahare, R.; Korthikunta, V.; Chandasana, H.; Suthar, M. K.; Agnihotri, P.; Vishwakarma, P.; Chaitanya, T. K.; Kancharla P. R.; Khaliq, T.; Gupta, S.; Bhatta, R. S.; Pratap, V. J.; Saxena, J. K.; Gupta, S.; Narender, T. Synthesis, structure-activity relationships and biological studies of chromeno-chalcones as potential antileishmanial agents. J. Med. Chem. 2014, 57, 3342–3357. (Currently among the most read articles)

7. Narender, T.; Korthikunta, V.; Gupta, S.; Kancharla P. R.; Khaliq, T.; Soni, A.; Srivastava, R. K.; Srivastava, K.; Puri, S. K.; Siva Rama Raju, K.; Wahajuddin, Sijwali, P. S.; Kumar, V.; Siddiqi, M. I. Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents. J. Med. Chem. 2013, 56, 31–45. (Highly read article of 2012)

8. Singh, V. K.; Mishra, V.; Tiwari, S.; Khaliq, T.; Barthwal, M. K.; Pandey, H. P.; Palit, G.; Narender, T. Antisecretory and cytoprotective effects of peganine hydrochloride isolated from the seeds of Peganum harmala on gastric ulcers. Phytomedicine, 2013, 20, 1180-1185.

9. Singh, A. B.; Khaliq, T.; Chaturvedi, J. P.; Narender, T.; Srivastava, A. K. Antidiabetic and antioxidative effects of 4-hydroxypipecolic acid in C57BL/KsJ-db/db mice. Hum. Exp. Toxicol. 2012, 31, 57-65.

10. Khaliq, T.; Sadilek, M.; Scott, R. C.; Turecek, F.; Gelb, M. H. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: Application to screening newborns for mucopolysaccharidosis IVA (morquio A). Clinical Chem. 2011, 57, 128-131.

11. Duffey, T. A.; Khaliq, T.; Scott, R. C.; Turecek, F.; Gelb, M. H. Design and synthesis of reagents for newborn screening of maroteaux-Lamy and morquio A syndromes. Bioorg. Med. Chem. Lett. 2010, 20, 5994-5996.

12. Duffey, T. A.; Gelb, M. H.; Scott, R. C.; Turecek, F.; Khaliq, T. Newborn screening for lysosomal storage disorders: Tandem mass spectrometry to quantitate enzymatic activity. Mol. Gen. Metabol. 2010, 99, S16.

13. Khaliq, T.; Misra, P.; Gupta, S.; Kancharla P. R.; Kant, R.; Maulik, P. R.; Dube, A.; Narender, T. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg. Med. Chem. Lett. 2009, 19, 2585-2586.

14. Narender, T.; Khaliq, T.; Singh, A. B.; Joshi, M. D.; Mishra, P.; Chaturvedi, J. P.; Srivastava, A. K.; Maurya, R.; Agarwal, S. C. Synthesis of α-amyrin derivatives and their in vivo antihyperglycemic activity. Eur. J. Med. Chem. 2009, 44, 1215-1222.

15. Misra, P.; Khaliq, T.; Dixit, A.; Sengupta, S.; Samant, M.; Kumari, S.; Kumar, A.; Kushawaha, P.; Majumder, H.; Saxena, A.; Narender, T.; Dube, A. Antileishmanial activity mediated by apoptosis and structure based target study of peganine hydrochloride dihydrate: An approach for rational drug designing. J. Antimicrob. Chemother. 2008, 62, 998-1002.

16. Narender, T.; Khaliq, T.; Srivastava, M. N. Naturally occurring 1, 1'-trimethylene bisuracil from the marine sea hare. Dolabella auricularia. Nat. Prod. Commun. 2007, 2, 7173.

17. Narender, T.; Khaliq, T. A new triterpenoid from Peganum harmala. Nat. Prod. Commun. 2007, 2, 1079-1081.

18. Narender, T.; Sahu, S.; Tiwari, P.; Kancharla P. R.; Khaliq, T.; Prathipati, P.; Puri, A.; Srivastava, A. K.; Chander, R.; Agarwal, S. C.; Raj, K. Antihyperglycemic and antidyslipidemic agent from Aegle marmelos. Bioorg. Med. Chem. Lett. 2007, 17, 1808-1811.

19. Roy, A. D.; Kumar, R.; Gupta, P.; Khaliq, T.; Narender, T.; Agarwal, V. L.; Roy, R. Xyloccensin X and Y, two new limonoids from Xylocarpus molluccensis: NMR investigation in mixture. Magn. Reson. Chem. 2006, 44, 1054-1057.

20. Narender, T.; Khaliq, T.; Puri, A.; Chander, R. Antidyslipidemic activity of furano-flavonoids isolated from Indigofera tinctoria. Bioorg. Med. Chem. Lett. 2006, 16, 3411-3414.

21. Narender, T.; Puri, A.; Shweta; Khaliq, T.; Saxena, R.; Bhatia, G.; Chandra, R. 4-Hydroxyisoleucine an unusual amino acid as antidyslipidemic and antihyperglycemic agent. Bioorg. Med. Chem. Lett. 2006, 16, 293–296.

22. Narender, T.; Shweta; Khaliq, T.; Rao, M. S.; Srivastava, K.; Puri, S. K. Prenylated chalcones isolated from Crotalaria genus inhibits in vitro growth of the human malaria parasite Plasmodium falciparum. Bioorg. Med. Chem. Lett. 2005, 15, 2453-2455.

23. Narender, T.; Khaliq, T.; Shweta; Nishi; Goyal, N.; Gupta, S. Synthesis of chromeno-chalcones and evaluation of their in vitro antileishmanial activity. Bioorg. Med. Chem. 2005, 13, 6543-6550.